With the mission of
Supply Vaccines to Eliminate Human DiseasesAbout SINOVAC
SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
SINOVAC Launches New Influenza Vaccine Production Facility
SINOVAC's Hepatitis A Vaccine Healive® Approved for Use in Egypt
SINOVAC has undertaken nearly 60 national and regional science and technology
R&D projects; received two State Scientific and Technology Progress Awards
and three national-level institutional technology awards; and published more than
140 SCI papers, many of which were published in top academic journals including
New England Journal of Medicine, The Lancet, Science and Nature, etc.
SINOVAC approved products include: COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®, Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®, Hepatitis A Vaccine (Human Diploid Cell) Inactivated - Healive®, Influenza Vaccine (Split Virion), Inactivated - Anflu®, 23-valent Pneumococcal Polysaccharide Vaccine, Varicella Vaccine(Live), Mumps Vaccine(Live), etc.
COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®
Validated by the World Health Organization's Emergency Use Listing ("EUL") Procedure on June 2, 2021
Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive®
Launched in 2016.
Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive®
Launched in 2002.
Influenza Vaccine Product Family
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent. Influenza Vaccine (Split Virion), Inactivated - Anflu®. Pandemic Influenza Vaccine (Inactivated, Adjuvanted) - Panflu®. H1N1 Influenza A Vaccine (Split Virion), Inactivated - Panflu.1®.
23-Valent Pneumococcal Polysaccharide Vaccine
Launched in 2020.
Varicella Vaccine, Live - PROVARIX
Launched in 2020.
Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains
Launched in 2021.
Launched in 2012.